Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Alcohol abuse remains a significant cause of preventable morbidity and mortality in the US. Yet only 15% of those with alcohol use disorders receive treatment. Contingency Management (CM) is a cost-effective intervention for drug addiction where individuals are rewarded when they submit biological verification of drug abstinence. The researchers propose to develop an integrated CM system capable of incorporating mobile device input, that would allow them to deliver a CM intervention for problematic drinking to anyone who owns a smartphone. The mobile device input will incorporate ecological momentary assessments (EMA), geospatial mapping, and biomarker-based feedback from a portable measuring device.
The researchers propose to develop an integrated Contingency Management (CM) system capable of incorporating mobile device input, which would allow them to deliver a CM intervention for problematic drinking to anyone who owns a smartphone. The location of participants through their cell phone will be recorded. The researchers will be using this data to create a "heat-map" to find problem areas of drinking. The application works only on iPhone 7 or a newer version with an (iPhone Operating System) iOS 13.5. If the participant does not have an iPhone 7 or a newer version, the researcher can loan one to the participant if he/she knows how to use it, but it must be returned at the end of the study.
The primary aim is to combine mobile technology, geospatial mapping, and biomarker measurement, with individual goal setting and ecological momentary assessments (EMA) feedback to launch behavioral modification strategies and progress monitoring.
People can participate if they are 1) age 18-65 years; 2) have an Alcohol Use Disorders Identification Test (AUDIT) score of 8 or higher; 3) have the ability to read and speak English; 4) have the ability to provide written informed consent; 5) have a breath alcohol of 0.00 during informed consent, and 6) can operate a smartphone with an active service provider.
The researchers will utilize an A-B-A completely within-subject design with the intent of recruiting twenty total participants from the Community in Spokane.
During the first A phase, participants will receive reinforcement for simply submitting breath samples 3 times per day between 4 and 6 hours apart.
During the B phase, the delivery of reinforcers will be contingent upon the submission of an alcohol negative breath sample on an escalating schedule.
The A phase or return to the baseline phase will involve the delivery reinforcers for simply submitting a sample during the designated windows of time.
The researchers will also collect other EMA data on stress, anxiety, depression, and other brief measures daily through participants' smartphone. Each phase will last a total of 4 weeks (i.e., 2 weeks of the first A phase, 4 weeks of the B phase, and then 2 more weeks of the A-phase) each for a total of 8 weeks of participation. Participants will be asked to submit 3 breath samples per day through a Bluetooth enabled breathalyzer developed by BACTrack no less than 8 hours apart and no more than 12 hours apart. Test results for breath alcohol will be available instantly to the participant and uploaded to the CM response system almost immediately.
As part of this CM system, participants will have the capability to receive multi-modal message reminders when they enter a new window of needed biochemical sample submission and additional reminders when the window of sample submission is about to close. While participants will receive information messages to this effect during the A phase, participants will receive additional personalized multi-modal message reminders once the CM platform can detect that they have entered a cold or hot zone. For example, upon entering a hot zone radius during the B phase wherein they had a greater 50% likelihood of drinking in that zone during the A phase, they will receive a text message encouraging them to change surroundings in order to better promote abstinence. Also, if the participant is within a window of time where they are eligible to submit a sample and receive a dose of reinforcement, this is another action that the individual can take to help bolster their attempt to remain abstinent. All these data (i.e., biochemical results, location of sample submission, time of submission, and other bits of data) will be collected and be presented in summary form to the research team. This will help the team devise an action plan if the participant's drinking behavior is proving impervious to intervention or if the participant's goals are being met, this is something the researcher can encourage about.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Contingency management A-B-A | Experimental | All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Contingency management | Behavioral | Reinforcement, or incentives, in exchange for evidence of not drinking alcohol. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Biochemically Measured Change in Alcohol Abstinence. | Change in biochemically measured alcohol abstinence assessed through breath samples submitted three times daily. | Daily during 8 weeks (2 weeks of first A phase, 4 weeks of B phase, and 2 second A phase) |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility Indicator of App Usage | Percentage of actual BAC samples submitted by the total number of possible submissions. | 8 weeks (2 weeks of first A phase, 4 weeks of B phase, and 2 second A phase) |
| Treatment Retention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington State University | Spokane | Washington | 99202 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Contingency Management A-B-A | All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods. Contingency management: Reinforcement, or incentives, in exchange for evidence of not drinking alcohol. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Contingency Management A-B-A | All participants will be assigned a single arm where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods. Contingency management: Reinforcement, or incentives, in exchange for evidence of not drinking alcohol. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Biochemically Measured Change in Alcohol Abstinence. | Change in biochemically measured alcohol abstinence assessed through breath samples submitted three times daily. | This is a within subject design (each participant goes through all three phases, the two A phases are control phases and B is the experimental phase). The overall number of units is total BAC submission for all phases. The numbers analyzed below differ based on total number of samples submitted by phase. | Posted | Number | Number of negative BAC samples by phase. | Daily during 8 weeks (2 weeks of first A phase, 4 weeks of B phase, and 2 second A phase) | Total BAC samples submitted | Total BAC samples submitted |
|
8 Weeks
Participants were asked once weekly at their visits about potential adverse events.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | First A Phase | All participants will be assigned a single arm within subject design, where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods. Participants were asked weekly about adverse events over the course of 8 weeks. This arm reflects the 2 weeks in first A phase. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Kidney Pain | Renal and urinary disorders | Systematic Assessment | Related to over consumption of alcohol during first A phase. Participant 1. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Abigail Bowen | Washington State University | (425) 736-1354 | abigail.bowen@wsu.edu |
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 9, 2020 | Nov 6, 2024 | Prot_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Jun 3, 2020 | Nov 6, 2024 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
A-B-A, or a return to baseline design.
Not provided
Not provided
Not provided
Not provided
Duration in weeks of treatment retention
| 8 Weeks |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Employment | Count of Participants | Participants |
|
| Baseline EtG Result | Count of Participants | Participants |
|
|
|
| Secondary | Feasibility Indicator of App Usage | Percentage of actual BAC samples submitted by the total number of possible submissions. | This is a within subject design (each participant goes through all three phases, the two A phases are control phases and B is the experimental phase). The overall number of units is total BAC submission for all phases. The numbers analyzed below differ based on total number of samples submitted by phase. | Posted | Number | BAC samples actually submitted by phase | 8 weeks (2 weeks of first A phase, 4 weeks of B phase, and 2 second A phase) | Total possible submissions of BAC sample | Total possible submissions of BAC sample |
|
|
|
| Secondary | Treatment Retention | Duration in weeks of treatment retention | Posted | Mean | Standard Deviation | Weeks | 8 Weeks |
|
|
|
| 0 |
| 12 |
| 0 |
| 12 |
| 2 |
| 12 |
| EG001 | B Phase | All participants will be assigned a single arm within subject design, where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods. Participants were asked weekly about adverse events over the course of 8 weeks. This arm reflects the 4 weeks in the experimental B phase. | 0 | 12 | 0 | 12 | 2 | 12 |
| EG002 | Second A Phase | All participants will be assigned a single arm within subject design, where we will utilize an A-B-A, or return to baseline design where all participants will experience the intervention in between two baseline observation periods. Participants were asked weekly about adverse events over the course of 8 weeks. This arm reflects the 2 weeks in the second A phase. | 0 | 12 | 0 | 12 | 0 | 12 |
|
| Mild headache | Nervous system disorders | Systematic Assessment | Mild headache believed to be due to wildfire smoke during first A phase. Participant 5. |
|
| Sleep apnea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment | Sleep apnea believed to be due to smoking during B phase. Participant 1. |
|
| Shoulder pain | Musculoskeletal and connective tissue disorders | Systematic Assessment | Injury to shoulder, treated with ice during B Phase. Participant 11. |
|
Not provided
Not provided
| B Phase |
|
|
| Second A Phase |
|
|